Treatment of non-Hodgkin's lymphoma of waldeyer's ring: Radiotherapy versus chemotherapy versus combined therapy

Avilés, Agustín; Delgado, S.; Ruiz, Henry E.; Torre, Antonio de la; Guzmán, Renaldo; Talavera, Alejandra

doi:10.1016/0964-1955(95)00058-5

Cited by 76 publications

(43 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gray dashed curves represent patients with and black curves represent patients without extralymphatic craniofacial involvement. [24][25][26] and (2) because neither prophylaxis with intrathecal MTX nor radiotherapy to these sites (except for cases of bulky [$7.5 cm] involvement of these lymphatic structures) were recommended, we did not include them in this study, the major objective of which was to analyze the role of prophylactic intrathecal MTX and radiotherapy to E CFI sites. A sensitivity analysis including the 731 patients with involvement of E CFI (290 patients) and the Waldeyer ring without E CFI (341 patients) yielded the same outcome results that we had obtained in patients with involvement of the other E CFI sites (data not shown).…”

Section: Discussionmentioning

confidence: 99%

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

Murawski

Held

Ziepert

et al. 2014

Blood

View full text Add to dashboard Cite

Key Points• The results of this retrospective analysis do not support intrathecal prophylaxis or radiotherapy to E CFI patients in complete remission/unconfirmed complete remission.To define the role of radiotherapy and intrathecal prophylaxis in extralymphatic craniofacial involvement (E CFI ) of aggressive B-cell lymphoma, we analyzed 11 consecutive German High-Grade Non-Hodgkin Lymphoma Study Group trials. E CFI occurred in 290/4155 (7.0%) patients (orbita, 31; paranasal sinuses, 93; main nasal cavity, 38; tongue, 27; remaining oral cavity, 99; salivary glands, 54). In a multivariable analysis adjusted for International Prognostic Index rituximab improved event-free and overall survival both in patients with and without E CFI . Three-year event-free (79% vs 79%; P 5 .842) and overall survival (86% vs 88%; P 5 .351) rates were similar in 145 patients receiving and 57 not receiving radiotherapy. Without rituximab, the 2-year cumulative rate of central nervous system (CNS) disease was increased in 205 E CFI patients compared with 2586 non-E CFI patients (4.2% vs 2.8%; P 5 .038), whereas this was not observed with rituximab (1.6% in 83 E CFI vs 3.4% in 1252 non-E CFI patients; P 5 .682). In 88 E CFI patients who received intrathecal prophylaxis with methotrexate, the 2-year rate of CNS disease was 4.2% compared with 2.3% in 191 patients who did not (P 5 .981). In conclusion, rituximab eliminates the increased risk for CNS disease in patients with E CFI . This retrospective analysis does not support intrathecal prophylaxis or radiotherapy to E CFI patients in complete remission/unconfirmed complete remission. These findings should be confirmed in a prospective study. (Blood. 2014;124(5):720-728)

show abstract

Section: Discussionmentioning

confidence: 99%

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

Murawski

Held

Ziepert

et al. 2014

Blood

View full text Add to dashboard Cite

show abstract

“…Three hundred and sixteen patients with aggressive lymphoma in stage I were randomized between radiotherapy alone, chemotherapy alone (CHOP or CHOP-like) and radiotherapy followed by chemotherapy. Failure-free (FFS) and overall survival (OS) at 5 years were significantly better in the combined modality group compared with either radiotherapy alone or chemotherapy alone (FFS, 83% vs. 48% vs. 43%; OS, 90% vs. 58% vs. 56%) (72). In this study radiotherapy was given before chemotherapy but in reviews chemotherapy before radiotherapy is advocated (69,71,73).…”

Section: Total Body Irradiation (Tbi)mentioning

confidence: 99%

A Systematic Overview of Radiation Therapy Effects in Non-Hodgkin's Lymphoma

2003

View full text Add to dashboard Cite

“…In contrast, in all patients with NHL of Waldeyer ring, the tonsil was the most frequently involved site, accounting for 50% to 80% of all primary lesions. 28,30,[35][36][37][38] Primary patterns of failure were both nodal and distant extranodal spread for WR-NKTL. In contrast, the most common sites of failure were extranodal dissemination only for patients with nasal NK/T-cell lymphoma or nasal-type NK/T-cell lymphoma of the extra-upper aerodigestive tract.…”

Section: Clinical Featuresmentioning

confidence: 99%

Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring

Fang

et al. 2008

Blood

101

100

View full text Add to dashboard Cite

Treatment of non-Hodgkin's lymphoma of waldeyer's ring: Radiotherapy versus chemotherapy versus combined therapy

Cited by 76 publications

References 26 publications

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

A Systematic Overview of Radiation Therapy Effects in Non-Hodgkin's Lymphoma

Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring

Contact Info

Product

Resources

About